Disclosure of interest: Edoardo Ricci: nothing to disclose, Giovanni Furlanis: nothing to disclose, Milos Ajevi: nothing to disclose, Emanuele Vincis: nothing to disclose, Gabriele Prandin: nothing to disclose, Laura Mancinelli: nothing to disclose, Federica Palacino: nothing to disclose, Magda Quagliotto: nothing to disclose, Paola Caruso: nothing to disclose, Marcello Naccarato: nothing to disclose, Paolo Manganotti: nothing to disclose E-Posters - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P2081 - ESOC25-1546 ADVANCE CONSENT FOR PARTICIPATION IN ACUTE STROKE TRIALS (ACTION): 6-MONTH RESULTS OF A FEASIBILITY STUDY Michel Shamy 1,2 , Ubong Udoh 1 , Emma Cummings 1 , Rena Patricia Seeger 2 , Brian Dewar 1 , Dar Dowlatshahi 1,2 1 Ottawa Hospital Research Institute, Ottawa, Canada, 2 Department of Medicine, University of Ottawa, Ottawa, Canada Background and Aims: Obtaining consent for participation in acute stroke trials is widely recognized as a significant challenge
MicroRNAs in intervertebral disc degeneration, apoptosis, inflammation, and mechanobiology
The distinction between a protocol that drives genuine 3050 % faster healing and one that barely moves the needle often comes down to whether the loading phase was completed correctly
A history of heart disease
Pentadeca Arginate, an enhanced analog of BPC-157, is designed to work with those processes to help support recovery, promote a healthy inflammatory response, and encourage digestive wellness
